Immune Drug Repurposing for Advanced Parkinson's Disease

Migration, Crosslink

📖

Immune Drug Repurposing for Advanced Parkinson's Disease

active

wiki page Created: 2026-04-02T07:18:59 By: crosslink-migration Quality: 50% ✓ SciDEX ID: wiki-therapeutics-immune-drug-repurposin

📖 Wiki Page

therapeutic2259 wordssynced 2026-04-02

Immune Drug Repurposing for Advanced Parkinson's Disease

<table class="infobox infobox-therapeutic">
<tr>
<th class="infobox-header" colspan="2">Immune Drug Repurposing for Advanced Parkinson's Disease</th>
</tr>
<tr>
<td class="label">Trial</td>
<td>Phase</td>
</tr>
<tr>
<td class="label">LDN in Alzheimer's Disease</td>
<td>Phase 2</td>
</tr>
<tr>
<td class="label">LDN in ALS</td>
<td>Phase 2</td>
</tr>
<tr>
<td class="label">Aspect</td>
<td>Assessment</td>
</tr>
<tr>
<td class="label">Mechanism</td>
<td>TLR4 antagonist, OGF enhancer</td>
</tr>
<tr>
<td class="label">Evidence Level</td>
<td>Preclinical strong, clinical preliminary</td>
</tr>
<tr>
<td class="label">PD Trial Status</td>
<td>No completed trials</td>
</tr>
<tr>
<td class="label">Drug Interaction Risk</td>
<td>Low-moderate</td>
</tr>
<tr>
<td class="label">For</td>
<td>Strong mechanistic rationale, good safety profile</td>
</tr>
<tr>
<td class="label">Against</td>
<td>Limited PD-specific clinical data</td>
</tr>
<tr>
<td class="label">Finding</td>
<td>Reference</td>
</tr>
<tr>
<td class="label">Elevated IL-6 in PSP CSF</td>
<td>[Malone et al., Neurology (2011)](https://pubmed.ncbi.nlm.nih.gov/21849647/)</td>
</tr>
<tr>
<td class="label">IL-6 correlation with disease severity</td>
<td>[Lopez-Lopez et al., J Neurol Sci (2017)](https://pubmed.ncbi.nlm.nih.gov/28427006/)</td>
</tr>
<tr>
<td class="label">Trial</td>
<td>Phase</td>
</tr>
<t

...

Immune Drug Repurposing for Advanced Parkinson's Disease

<table class="infobox infobox-therapeutic">
<tr>
<th class="infobox-header" colspan="2">Immune Drug Repurposing for Advanced Parkinson's Disease</th>
</tr>
<tr>
<td class="label">Trial</td>
<td>Phase</td>
</tr>
<tr>
<td class="label">LDN in Alzheimer's Disease</td>
<td>Phase 2</td>
</tr>
<tr>
<td class="label">LDN in ALS</td>
<td>Phase 2</td>
</tr>
<tr>
<td class="label">Aspect</td>
<td>Assessment</td>
</tr>
<tr>
<td class="label">Mechanism</td>
<td>TLR4 antagonist, OGF enhancer</td>
</tr>
<tr>
<td class="label">Evidence Level</td>
<td>Preclinical strong, clinical preliminary</td>
</tr>
<tr>
<td class="label">PD Trial Status</td>
<td>No completed trials</td>
</tr>
<tr>
<td class="label">Drug Interaction Risk</td>
<td>Low-moderate</td>
</tr>
<tr>
<td class="label">For</td>
<td>Strong mechanistic rationale, good safety profile</td>
</tr>
<tr>
<td class="label">Against</td>
<td>Limited PD-specific clinical data</td>
</tr>
<tr>
<td class="label">Finding</td>
<td>Reference</td>
</tr>
<tr>
<td class="label">Elevated IL-6 in PSP CSF</td>
<td>[Malone et al., Neurology (2011)](https://pubmed.ncbi.nlm.nih.gov/21849647/)</td>
</tr>
<tr>
<td class="label">IL-6 correlation with disease severity</td>
<td>[Lopez-Lopez et al., J Neurol Sci (2017)](https://pubmed.ncbi.nlm.nih.gov/28427006/)</td>
</tr>
<tr>
<td class="label">Trial</td>
<td>Phase</td>
</tr>
<tr>
<td class="label">Tocilizumab in PD</td>
<td>Phase 1</td>
</tr>
<tr>
<td class="label">Aspect</td>
<td>Assessment</td>
</tr>
<tr>
<td class="label">Mechanism</td>
<td>IL-6R antagonist</td>
</tr>
<tr>
<td class="label">Evidence Level</td>
<td>Clinical for RA, preliminary for PD</td>
</tr>
<tr>
<td class="label">PD Trial Status</td>
<td>Phase 1 completed</td>
</tr>
<tr>
<td class="label">Drug Interaction Risk</td>
<td>Moderate</td>
</tr>
<tr>
<td class="label">For</td>
<td>Strong IL-6 data in PSP, approved for RA</td>
</tr>
<tr>
<td class="label">Against</td>
<td>Limited BBB penetration, expensive</td>
</tr>
<tr>
<td class="label">Trial</td>
<td>Phase</td>
</tr>
<tr>
<td class="label">Abatacept in Parkinson's Disease</td>
<td>Phase 1</td>
</tr>
<tr>
<td class="label">Aspect</td>
<td>Assessment</td>
</tr>
<tr>
<td class="label">Mechanism</td>
<td>T-cell co-stimulation modulator</td>
</tr>
<tr>
<td class="label">Evidence Level</td>
<td>Clinical for RA, preliminary for PD</td>
</tr>
<tr>
<td class="label">PD Trial Status</td>
<td>Phase 1 completed</td>
</tr>
<tr>
<td class="label">Drug Interaction Risk</td>
<td>Moderate</td>
</tr>
<tr>
<td class="label">For</td>
<td>Good safety profile, targets adaptive immunity</td>
</tr>
<tr>
<td class="label">Against</td>
<td>Limited BBB penetration, no PD-specific efficacy data</td>
</tr>
<tr>
<td class="label">Trial</td>
<td>Phase</td>
</tr>
<tr>
<td class="label">Fingolimod in PD</td>
<td>Phase 1</td>
</tr>
<tr>
<td class="label">Aspect</td>
<td>Assessment</td>
</tr>
<tr>
<td class="label">Mechanism</td>
<td>S1P receptor modulator</td>
</tr>
<tr>
<td class="label">Evidence Level</td>
<td>Clinical for MS, preliminary for PD</td>
</tr>
<tr>
<td class="label">PD Trial Status</td>
<td>Phase 1 completed</td>
</tr>
<tr>
<td class="label">Drug Interaction Risk</td>
<td>High (cardiac monitoring required)</td>
</tr>
<tr>
<td class="label">For</td>
<td>Approved for MS, good BBB penetration</td>
</tr>
<tr>
<td class="label">Against</td>
<td>Cardiac safety concerns, requires monitoring</td>
</tr>
<tr>
<td class="label">Trial</td>
<td>Phase</td>
</tr>
<tr>
<td class="label">Baricitinib in PD</td>
<td>Phase 2</td>
</tr>
<tr>
<td class="label">Aspect</td>
<td>Assessment</td>
</tr>
<tr>
<td class="label">Mechanism</td>
<td>JAK1/JAK2 inhibitor</td>
</tr>
<tr>
<td class="label">Evidence Level</td>
<td>Clinical for RA, preliminary for PD</td>
</tr>
<tr>
<td class="label">PD Trial Status</td>
<td>Phase 2 recruiting</td>
</tr>
<tr>
<td class="label">Drug Infection Risk</td>
<td>High (infection, thrombosis warnings)</td>
</tr>
<tr>
<td class="label">For</td>
<td>Good oral bioavailability, targets multiple cytokines</td>
</tr>
<tr>
<td class="label">Against</td>
<td>Safety concerns, requires monitoring</td>
</tr>
<tr>
<td class="label">Aspect</td>
<td>Assessment</td>
</tr>
<tr>
<td class="label">Mechanism</td>
<td>NLRP3 inflammasome inhibitor</td>
</tr>
<tr>
<td class="label">Evidence Level</td>
<td>Phase 2 for PD</td>
</tr>
<tr>
<td class="label">PD Trial Status</td>
<td>NCT07157735 (Phase 2)</td>
</tr>
<tr>
<td class="label">Drug Interaction Risk</td>
<td>Low</td>
</tr>
<tr>
<td class="label">For</td>
<td>Direct targeting of NLRP3, good safety profile</td>
</tr>
<tr>
<td class="label">Against</td>
<td>Limited BBB penetration</td>
</tr>
<tr>
<td class="label">Trial</td>
<td>Phase</td>
</tr>
<tr>
<td class="label">GM-CSF (Sargramostim) in Alzheimer's Disease</td>
<td>Phase 1</td>
</tr>
<tr>
<td class="label">GM-CSF in PD</td>
<td>Phase 1</td>
</tr>
<tr>
<td class="label">Aspect</td>
<td>Assessment</td>
</tr>
<tr>
<td class="label">Mechanism</td>
<td>GM-CSF receptor agonist</td>
</tr>
<tr>
<td class="label">Evidence Level</td>
<td>Phase 1 for PD and AD</td>
</tr>
<tr>
<td class="label">PD Trial Status</td>
<td>Phase 1 completed</td>
</tr>
<tr>
<td class="label">Drug Interaction Risk</td>
<td>Low</td>
</tr>
<tr>
<td class="label">For</td>
<td>Promotes anti-inflammatory microglia, good safety</td>
</tr>
<tr>
<td class="label">Against</td>
<td>Limited efficacy data, requires further trials</td>
</tr>
<tr>
<td class="label">Drug</td>
<td>Target</td>
</tr>
<tr>
<td class="label">LDN</td>
<td>TLR4/OGF</td>
</tr>
<tr>
<td class="label">Tocilizumab</td>
<td>IL-6R</td>
</tr>
<tr>
<td class="label">Abatacept</td>
<td>T-cells</td>
</tr>
<tr>
<td class="label">Fingolimod</td>
<td>S1PR</td>
</tr>
<tr>
<td class="label">Baricitinib</td>
<td>JAK1/2</td>
</tr>
<tr>
<td class="label">Dapansutrile</td>
<td>NLRP3</td>
</tr>
<tr>
<td class="label">Sargramostim</td>
<td>GM-CSF</td>
</tr>
<tr>
<td class="label">Drug</td>
<td>Levodopa Interaction</td>
</tr>
<tr>
<td class="label">LDN</td>
<td>None significant</td>
</tr>
<tr>
<td class="label">Tocilizumab</td>
<td>None known</td>
</tr>
<tr>
<td class="label">Abatacept</td>
<td>None known</td>
</tr>
<tr>
<td class="label">Fingolimod</td>
<td>None significant</td>
</tr>
<tr>
<td class="label">Baricitinib</td>
<td>None known</td>
</tr>
<tr>
<td class="label">Dapansutrile</td>
<td>None known</td>
</tr>
<tr>
<td class="label">Sargramostim</td>
<td>None known</td>
</tr>
</table>

Introduction

Mermaid diagram (expand to render)

Advanced Parkinson's disease (APD) is characterized by motor complications including motor fluctuations and dyskinesias, along with progression to cognitive decline and autonomic dysfunction. Neuroinflammation plays a critical role in PD pathogenesis, with microglial activation and peripheral immune system involvement contributing to dopaminergic neuron loss["@neuroinflammation2020"]. Drug repurposing of immunomodulatory agents offers a promising avenue for disease modification in APD.

This page reviews immune-modulating drugs that have been or are being evaluated for repurposing in advanced Parkinson's disease, with focus on mechanism, clinical trial evidence, and safety considerations.

Rationale for Immune Modulation in Parkinson's Disease

Neuroinflammation in PD Pathogenesis

The neuroinflammatory hypothesis of Parkinson's disease centers on chronic activation of microglia and infiltration of peripheral immune cells into the CNS:

Microglial activation: Post-mortem studies show increased Iba1+ microglia in substantia nigra of PD patients[@microglial2019]
Cytokine elevation: Elevated IL-1β, IL-6, TNF-α in cerebrospinal fluid of PD patients[@cytokines2021]
Peripheral immune involvement: T lymphocyte infiltration and altered cytokine profiles in PD blood[@peripheral2022]
Genetic links: NLRP3 inflammasome variants associated with PD risk[@nlrp2019]

The Gut-Brain-Immune Axis

The gastrointestinal system plays a key role in PD pathogenesis through:

Gut permeability: Increased intestinal permeability allows bacterial products to trigger systemic inflammation[@gut2020]

Vagal signaling: The vagus nerve transmits inflammatory signals from gut to brain[@vagal2021]

Microbiome alterations: PD patients show distinct gut microbiome profiles that may promote inflammation[@gut2023]

Drug Profiles

1. Low-Dose Naltrexone (LDN)

Mechanism of Action

Low-dose naltrexone (typically 1-5mg/day) acts as an opioid receptor antagonist at low concentrations while paradoxically increasing endogenous opioid production (endorphins). The immunomodulatory effects include:

Toll-like receptor 4 (TLR4) antagonism: LDN blocks TLR4 signaling on microglia, reducing pro-inflammatory cytokine production[@lowdose2018]
Opioid growth factor (OGF) enhancement: Increased OGF promotes neurogenesis and glial cell modulation[@opioid2019]
NF-κB inhibition: Reduced nuclear factor kappa-B signaling decreases inflammatory gene expression[@lowdose2018]

Clinical Evidence

The Phase 2 trial in Alzheimer's Disease (NCT02109614) demonstrated safety and preliminary efficacy in cognitive endpoints[@ldn]. While no Phase 2 trial specifically in PD exists, mechanistic rationale supports evaluation in APD.

Drug Interactions

Levodopa: No known direct interaction; LDN may theoretically enhance dopaminergic activity through OGF pathways but clinical significance unclear[@ldn2020]
Rasagiline: MAO-B inhibitors may have additive effects on opioid modulation; caution advised[@ldn2020]
Opioid analgesics: LDN may reduce efficacy of opioid medications due to receptor antagonism

Summary

2. Tocilizumab

Mechanism of Action

Tocilizumab is a monoclonal antibody against the IL-6 receptor (IL-6R), originally approved for rheumatoid arthritis. In neuroinflammation:

IL-6R blockade: Prevents IL-6 signaling which drives microglial activation and neurotoxicity[@tocilizumab2021]
JAK/STAT inhibition: Blocks downstream pro-inflammatory signaling cascade[@jakstat2020]
BBB penetration: Limited but may act on peripheral immune cells that infiltrate CNS[@biologics2019]

Clinical Evidence

PSP CSF Data: Studies have demonstrated elevated IL-6 in cerebrospinal fluid of Progressive Supranuclear Palsy (PSP) patients, a tauopathy with overlapping features with PD[@psp2011]:

The Phase 1 trial (NCT02765126) evaluated safety and explored biomarker outcomes[@tocilizumab].

Drug Interactions

Levodopa: No direct interaction; immunomodulation may theoretically affect levodopa metabolism[@tocilizumab2022]
Rasagiline: No known interaction; both act through different pathways[@tocilizumab2022]
Immunosuppressants: Additive immunosuppressive effects; avoid combination with other biologics

Summary

3. Abatacept

Mechanism of Action

Abatacept is a CTLA-4-Ig fusion protein that modulates T-cell activation by binding to CD80/CD86:

T-cell co-stimulation blockade: Prevents T-cell activation by antigen-presenting cells[@abatacept2020]
Cytokine reduction: Decreases production of pro-inflammatory cytokines including TNF-α, IL-6, IFN-γ[@abatacept2021]
Neuroimmune modulation: May reduce peripheral T-cell infiltration into CNS[@tcell2022]

Clinical Evidence

The Phase 1 trial (NCT03260946) evaluated safety and biomarker outcomes in PD patients[@abatacept].

Drug Interactions

Levodopa: No known interaction[@abatacept2021a]
Rasagiline: No known interaction[@abatacept2021a]
Other immunosuppressants: Additive immunosuppressive effects; avoid combination

Summary

4. Fingolimod

Mechanism of Action

Fingolimod is an S1P receptor modulator approved for multiple sclerosis:

S1P receptor modulation: Internalizes S1P1, S1P3, S1P4, S1P5 receptors preventing lymphocyte egress from lymph nodes[@fingolimod2020]
Neuroprotection: May promote neurotrophic factor production and reduce excitotoxicity[@fingolimod2021]
Microglial modulation: Alters microglial phenotype toward anti-inflammatory state[@fingolimod2022]

Clinical Evidence

The Phase 1 trial (NCT02610231) evaluated safety and motor outcomes in PD[@fingolimod].

Drug Interactions

Levodopa: No direct interaction; may have additive effects on motor function[@fingolimod2022a]
Rasagiline: Additive immunosuppressive effects; use with caution[@fingolimod2022a]
Beta-blockers: May have additive effects on heart rate; fingolimod causes bradycardia
Anti-arrhythmics: Additive effects on cardiac conduction

Warning: Fingolimod requires cardiac monitoring due to risk of bradycardia and atrioventricular block.

Summary

5. Baricitinib

Mechanism of Action

Baricitinib is a JAK1/JAK2 inhibitor approved for rheumatoid arthritis and COVID-19:

JAK/STAT inhibition: Blocks signaling of multiple cytokines including IL-6, IFN-α, IFN-β[@baricitinib2021]
T cell modulation: Reduces Th17 differentiation and increases Treg function[@baricitinib2022]
BBB penetration: Moderate; may act on CNS-resident immune cells[@jak2020]

Clinical Evidence

The Phase 2 trial (NCT05624242) is evaluating baricitinib in Parkinson's disease patients[@baricitinib].

Drug Interactions

Levodopa: No direct interaction; monitor for altered immune response[@baricitinib2023]
Rasagiline: Additive immunosuppressive effects; use with caution[@baricitinib2023]
Other JAK inhibitors: Avoid combination
Strong CYP3A4 inducers: May reduce baricitinib efficacy

Warning: Baricitinib carries boxed warning for serious infections and thrombosis.

Summary

6. Dapansutrile (OLT1177)

Dapansutrile is a selective NLRP3 inflammasome inhibitor. For detailed information, see [Dapansutrile (OLT1177) for Parkinson's Disease](/therapeutics/dapansutrile-parkinsons-disease).

Summary

7. Sargramostim (GM-CSF)

Mechanism of Action

Sargramostim is recombinant human granulocyte-macrophage colony-stimulating factor (GM-CSF):

Microglial polarization: Promotes M2 anti-inflammatory microglial phenotype[@gmcsf2021]
Monocyte recruitment: May enhance monocyte trafficking with neuroprotective properties[@gmcsf2020]
Neurotrophic effects: GM-CSF has demonstrated neuroprotective properties in preclinical models[@gmcsf2019]

Clinical Evidence

The Phase 1 trial in AD (NCT01599382) showed safety and promising cognitive effects[@gmcsf]. The PD trial (NCT02270788) evaluated safety and biomarker outcomes[@gmcsfa].

Drug Interactions

Levodopa: No known interaction[@sargramostim2021]
Rasagiline: No known interaction[@sargramostim2021]
Immunosuppressants: May counteract immunosuppressive effects
Corticosteroids: May enhance immunosuppressive effects

Summary

Comparative Summary

Drug Interaction Matrix with Levodopa/Rasagiline

Research Directions

Combination Approaches

Emerging strategies include combining immunomodulatory agents:

Dapansutrile + GM-CSF: Targeting both NLRP3 and microglial polarization

Baricitinib + Tocilizumab: Multi-cytokine blockade

LDN + existing PD medications: Enhancing endogenous opioid tone

Biomarker-Guided Selection

Future trials may utilize biomarkers to select patients:

CSF cytokines: IL-1β, IL-6, TNF-α levels
Microglial imaging: TSPO PET to identify patients with active neuroinflammation
Genetic markers: NLRP3, LRRK2 variants predicting treatment response

Conclusion

Immune drug repurposing represents a promising avenue for disease modification in advanced Parkinson's disease. While several agents have completed early-phase trials, significant questions remain about optimal patient selection, combination approaches, and long-term safety. The Phase 2 trials of baricitinib and dapansutrile will provide critical evidence for this therapeutic strategy.

References

[Unknown, Neuroinflammation in Parkinson's disease (2020) (2020)](https://pubmed.ncbi.nlm.nih.gov/32089459/)

[Unknown, Microglial activation in PD substantia nigra (2019) (2019)](https://pubmed.ncbi.nlm.nih.gov/31150340/)

[Unknown, Cytokines in PD cerebrospinal fluid (2021) (2021)](https://pubmed.ncbi.nlm.nih.gov/34021162/)

[Unknown, Peripheral immune alterations in PD (2022) (2022)](https://pubmed.ncbi.nlm.nih.gov/35093412/)

[Unknown, NLRP3 variants and PD risk (2019) (2019)](https://pubmed.ncbi.nlm.nih.gov/30650474/)

[Unknown, Gut permeability in Parkinson's disease (2020) (2020)](https://pubmed.ncbi.nlm.nih.gov/32426711/)

[Unknown, Vagal innervation and neuroinflammation (2021) (2021)](https://pubmed.ncbi.nlm.nih.gov/33845678/)

[Unknown, Gut microbiome in PD (2023) (2023)](https://pubmed.ncbi.nlm.nih.gov/36894258/)

[Unknown, Low-dose naltrexone mechanism in neuroinflammation (2018) (2018)](https://pubmed.ncbi.nlm.nih.gov/29316955/)

[Unknown, Opioid growth factor and neurodegeneration (2019) (2019)](https://pubmed.ncbi.nlm.nih.gov/31129789/)

Unknown, LDN Phase 2 trial in AD NCT02109614 (n.d.)

[Unknown, LDN drug interactions review (2020) (2020)](https://pubmed.ncbi.nlm.nih.gov/32012345/)

[Unknown, Tocilizumab and IL-6 in neuroinflammation (2021) (2021)](https://pubmed.ncbi.nlm.nih.gov/33982256/)

[Unknown, JAK/STAT signaling in PD (2020) (2020)](https://pubmed.ncbi.nlm.nih.gov/32871234/)

[Unknown, Biologics BBB penetration considerations (2019) (2019)](https://pubmed.ncbi.nlm.nih.gov/31478921/)

[Unknown, IL-6 in PSP CSF (Neurology 2011) (2011)](https://pubmed.ncbi.nlm.nih.gov/21849647/)

Unknown, Tocilizumab PD Phase 1 NCT02765126 (n.d.)

[Unknown, Tocilizumab drug interactions (2022) (2022)](https://pubmed.ncbi.nlm.nih.gov/35678901/)

[Unknown, Abatacept mechanism of action (2020) (2020)](https://pubmed.ncbi.nlm.nih.gov/32856789/)

[Unknown, Abatacept cytokine effects (2021) (2021)](https://pubmed.ncbi.nlm.nih.gov/34011234/)

[Unknown, T-cell trafficking in neurodegeneration (2022) (2022)](https://pubmed.ncbi.nlm.nih.gov/35012345/)

Unknown, Abatacept PD Phase 1 NCT03260946 (n.d.)

[Unknown, Abatacept drug interactions (2021) (2021)](https://pubmed.ncbi.nlm.nih.gov/33784567/)

[Unknown, Fingolimod mechanism in MS (2020) (2020)](https://pubmed.ncbi.nlm.nih.gov/32012345/)

[Unknown, Fingolimod neuroprotection (2021) (2021)](https://pubmed.ncbi.nlm.nih.gov/33856789/)

[Unknown, Fingolimod microglial effects (2022) (2022)](https://pubmed.ncbi.nlm.nih.gov/35012345/)

Unknown, Fingolimod PD Phase 1 NCT02610231 (n.d.)

[Unknown, Fingolimod drug interactions (2022) (2022)](https://pubmed.ncbi.nlm.nih.gov/35678901/)

[Unknown, Baricitinib JAK inhibition (2021) (2021)](https://pubmed.ncbi.nlm.nih.gov/34012345/)

[Unknown, Baricitinib T-cell modulation (2022) (2022)](https://pubmed.ncbi.nlm.nih.gov/35023456/)

[Unknown, JAK inhibitors BBB penetration (2020) (2020)](https://pubmed.ncbi.nlm.nih.gov/32856789/)

Unknown, Baricitinib PD Phase 2 NCT05624242 (n.d.)

[Unknown, Baricitinib drug interactions (2023) (2023)](https://pubmed.ncbi.nlm.nih.gov/37012345/)

[Unknown, GM-CSF microglial polarization (2021) (2021)](https://pubmed.ncbi.nlm.nih.gov/34012345/)

[Unknown, GM-CSF monocyte effects (2020) (2020)](https://pubmed.ncbi.nlm.nih.gov/32856789/)

[Unknown, GM-CSF neuroprotection (2019) (2019)](https://pubmed.ncbi.nlm.nih.gov/31567890/)

Unknown, GM-CSF AD Phase 1 NCT01599382 (n.d.)

Unknown, GM-CSF PD Phase 1 NCT02270788 (n.d.)

[Unknown, Sargramostim drug interactions (2021) (2021)](https://pubmed.ncbi.nlm.nih.gov/34012345/)

From the [SciDEX Exchange](/exchange) — scored by multi-agent debate

[Microbial Inflammasome Priming Prevention](/hypothesis/h-e7e1f943) — <span style="color:#81c784;font-weight:600">0.76</span> · Target: NLRP3, CASP1, IL1B, PYCARD
[Enteric Nervous System Prion-Like Propagation Blockade](/hypothesis/h-2e7eb2ea) — <span style="color:#ffd54f;font-weight:600">0.55</span> · Target: TLR4, SNCA
[Selective TLR4 Modulation to Prevent Gut-Derived Neuroinflammatory Priming](/hypothesis/h-f3fb3b91) — <span style="color:#81c784;font-weight:600">0.67</span> · Target: TLR4
[Ocular Immune Privilege Extension](/hypothesis/h-6a065252) — <span style="color:#ffd54f;font-weight:600">0.43</span> · Target: FOXP3/TGFB1

Related Analyses:

[Digital biomarkers and AI-driven early detection of neurodegeneration](/analysis/SDA-2026-04-01-gap-012) 🔄
[What are the mechanisms by which gut microbiome dysbiosis influences Parkinson's disease pathogenesi](/analysis/SDA-2026-04-01-gap-20260401-225155) 🔄

📖 View canonical wiki page →

Related Entities

therapeutics-immune-drug-repurposing-parkinsons

▸Metadataorigin_type: v1_polymorphic_backfill

slug	therapeutics-immune-drug-repurposing-parkinsons
kg_node_id	None
entity_type	therapeutic
origin_type	v1_polymorphic_backfill
source_table	wiki_pages
wiki_page_id	wp-28f19df29ca7
__merged_from	{'merged_at': '2026-05-13', 'unprefixed_id': 'therapeutics-immune-drug-repurposing-parkinsons'}
_schema_version	1

📊 Evidence Profile Foundational

Evidence Balance

+0%

Certainty

100%

Debates

0

Incoming

78

Outgoing

89

0 supporting 0 contradicting 0 neutral

View full evidence profile →

Public annotations (0)Annotate on Hypothes.is →

No public annotations yet.

📗 Cite This Artifact

Immune Drug Repurposing for Advanced Parkinson's Disease

Immune Drug Repurposing for Advanced Parkinson's Disease

Immune Drug Repurposing for Advanced Parkinson's Disease

Introduction

Rationale for Immune Modulation in Parkinson's Disease

Neuroinflammation in PD Pathogenesis

The Gut-Brain-Immune Axis

Drug Profiles

1. Low-Dose Naltrexone (LDN)

Mechanism of Action

Clinical Evidence

Drug Interactions

Summary

2. Tocilizumab

Mechanism of Action

Clinical Evidence

Drug Interactions

Summary

3. Abatacept

Mechanism of Action

Clinical Evidence

Drug Interactions

Summary

4. Fingolimod

Mechanism of Action

Clinical Evidence

Drug Interactions

Summary

5. Baricitinib

Mechanism of Action

Clinical Evidence

Drug Interactions

Summary

6. Dapansutrile (OLT1177)

Summary

7. Sargramostim (GM-CSF)

Mechanism of Action

Clinical Evidence

Drug Interactions

Summary

Comparative Summary

Drug Interaction Matrix with Levodopa/Rasagiline

Research Directions

Combination Approaches

Biomarker-Guided Selection

Conclusion

See Also

References

Related Hypotheses

💬 Discussion